Severo Ochoa Programme 2018-2022 Health NEWS

Wednesday, 16 November 2022

Three new ICN2 projects receive AGAUR 2021 Grants

Thanks to this funding, researchers at the ICN2 will develop photo-sensitive materials for smart windows, membranes for skin regeneration and a device for rapid detection and discrimination of respiratory viruses.

Monday, 05 September 2022

A DNA-based nanostructure inspired by antibodies as the core of a programmable sensing platform for rapid, single-step diagnostics

A team consisting of current and former members of the ICN2 Nanobioelectronics and Biosensors Group has developed an electrochemical sensor based on a modified DNA scaffold nanostructure able to detect antibodies and proteins in unprocessed biological fluids. It has a Y-shaped architecture that mimics the one of natural Immunoglobulin antibodies. According to the results published in an article in ‘Advanced Functional Materials’, it is selective, specific, and adaptable to the detection of different biomarkers.

Monday, 30 May 2022

Severo Ochoa Workshop on the Present and Future of Nanomedicine

The event, which was organised by group leader Prof. Laura Lechuga and counted on the participation of many members of the ICN2 community, aimed at bringing together researchers in the field of nanomedicine, clinicians from relevant hospitals, and healthcare industry experts to share results and views both on recent advances in the field and on effective procedures to transfer new technologies into clinical practice.

Tuesday, 15 March 2022

INBRAIN Neuroelectronics signs an agreement to develop neurotechnology patented by six public research institutions

INBRAIN Neuroelectronics is a technology company developing graphene-based applications for neurological diseases founded by researchers from IMB-CNM-CSIC, ICN2 and ICREA who lead some of the research areas of the Graphene Flagship. The agreement paves the way for further development and industrialization of patented technology from CSIC, ICN2, ICREA, CIBERBBN, UAB and IDIBAPS.

Wednesday, 02 March 2022

A novel and clinically validated optical biosensor enables rapid and quantitative serological testing of COVID-19

An innovative nano-biosensor for fast, quantitative and accurate COVID-19 serology, which achieves the high reliability of specialised laboratory analysis with the short times and simplicity of rapid self-tests, has been developed by a team of researchers led by Prof. Laura M. Lechuga, head of the ICN2 NanoBiosensors and Bioanalytical Applications Group. This work has been developed in collaboration with the Vall d'Hebron University Hospital and Research Institute (VHIR, Barcelona) and the Hospital Clínic of Barcelona–IDIBAPS –which provided the clinical samples and the validation— and the Emerging Virus Unit of Aix-Marseille University (France).

Wednesday, 09 February 2022

GLEBioassay project receives funding from EuroNanoMed

A project aiming at the nano-monitoring of cancer immunotherapy efficiency through a graphene electrophoretic bioassay platform, GLEBioassay, is one of the ten selected in the 12th Joint Trasnational Call for funding of the EuroNanoMed platform. The consortium will be led by Prof. Arben Merkoçi.

Thursday, 13 January 2022

State of the art and prospects in AttoSens, techniques for detecting ultra-low concentrations of analytes

A paper in “Chemical Society Review” discusses the progress over the last ten years in the development of biological and chemical sensing platforms for the detection of target analytes at ultra-low abundance level (attomolar). This work was coordinated by ICN2 group leader ICREA Prof. Arben Merkoçi and Prof. V.V.R. Sai, from the Indian Institute of Technology Madras (IITM).